Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer
Second Genome, Inc., a clinical-stage company focused on the development of novel therapeutics identified through microbiome science, today announced the appointment of Karim Dabbagh, Ph.D., as president, chief executive officer, and a member of the company's board of directors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,